Sergey G. Shcherbak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sergey G. Shcherbak has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Alexey Sergeevich Golota
Городская больница № 40 Курортного района. 191024, г. Сестрорецк, ул. Борисова, 9
20 shared publications Щербак Сергей Григорьевич
Санкт-Петербургский государственный университет; Городская больница № 40 Курортного административного района
20 shared publications- Dmitry Aleksandrovich Vologzhanin
Saint-Petersburg State University
19 shared publications - Tatyana A. Kamilova
Saint Petersburg City Hospital No. 40
18 shared publications - Svetlana Viacheslavovna Apalko
City Hospital No. 40, St. Petersburg 197706, Russia
17 shared publications - Andrey M. Sarana
Saint-Petersburg State University
13 shared publications
Latest Publications
- 5 October 2026
- Published by Pleiades Publishing Ltd in Russian Journal of Genetics
- Vol. 62 (10) , 1325-1335
Comparative Analysis of Next-Generation Sequencing Data Processing Methods for Small RNA
Next-generation sequencing is the most accurate method for discovering new genetic biomarkers. While working with small RNAs, processing and interpreting sequencing data is challenging. Using follicular thyroid neoplasms as an example, four methods for analyzing sequencing results were compared for 24 samples: follicular adenoma (n = 12) and follicular carcinoma (n = 12). Sequencing was performed on the DNBSEQ platform. Obtained data were analyzed by four approaches (MirMaster 2.0, Salmon, Star, and Python3), results were compared using a number of criteria and validated with RT-PCR for several representative molecules. For the analysis of small RNA (microRNA) sequencing data, the advantage of algorithms that align reads to reference sequences of mature microRNAs without mismatches and insertions was demonstrated.
- 5 October 2026
- Published by Pleiades Publishing Ltd in Russian Journal of Genetics
- Vol. 62 (10) , 1325-1335
Comparative Analysis of Next-Generation Sequencing Data Processing Methods for Small RNA
Next-generation sequencing is the most accurate method for discovering new genetic biomarkers. While working with small RNAs, processing and interpreting sequencing data is challenging. Using follicular thyroid neoplasms as an example, four methods for analyzing sequencing results were compared for 24 samples: follicular adenoma (n = 12) and follicular carcinoma (n = 12). Sequencing was performed on the DNBSEQ platform. Obtained data were analyzed by four approaches (MirMaster 2.0, Salmon, Star, and Python3), results were compared using a number of criteria and validated with RT-PCR for several representative molecules. For the analysis of small RNA (microRNA) sequencing data, the advantage of algorithms that align reads to reference sequences of mature microRNAs without mismatches and insertions was demonstrated.
- Open Access
- 18 May 2026
- Published by Federal Research and Clinical Center for Resuscitation and Rehabilitation in Physical and rehabilitation medicine, medical rehabilitation
- Vol. 8 (2) , 124-148
Epigenetic mechanisms in the pathogenesis of cardiovascular diseases and their significance for cardiac rehabilitation
The development and progression of cardiovascular diseases such as atherosclerosis, hypertension, coronary heart disease, heart failure, and others is determined by the interaction of genetic, environmental, and behavioral factors. In recent years, epigenetic mechanisms have been considered key regulators of the cardiovascular system, influencing gene expression without altering the DNA sequence. The expression of disease-associated genes is regulated by epigenetic mechanisms. The epigenome plays a key role in executing cellular programs, regulating gene transcription and altering chromatin structure and accessibility to transcription factors. Epigenetic enzymes depend on metabolites to perform their modifying functions, thereby establishing a link between metabolism and epigenetics. Cellular metabolic processes include glycolysis and β-oxidation of fatty acids, as well as energy metabolism. Cardiovascular metabolic dysfunction contributes to the development of cardiovascular disease through inappropriate epigenetic modifications of histone proteins, DNA, and RNA. Key elements of this process are transcription factors that interact with regulatory DNA sequences, altering gene expression. Advances in epigenome analysis have provided insights into the pathogenesis of cardiovascular diseases by identifying disease-associated epigenetic changes in cardiomyocytes and other cardiac cell types. This review examines recent discoveries in the field of epigenetic regulation of cardiac disease, highlighting the role of epigenetic enzymes and non-coding RNAs, which offer new opportunities for personalized medicine in cardiology. Understanding these epigenetic pathways is critical for the development of new biomarkers and epigenetic therapies and cardiac rehabilitation aimed at slowing or reversing maladaptive cardiac remodeling and improving clinical outcomes.
- 18 May 2026
- Published by Federal Research and Clinical Center for Resuscitation and Rehabilitation in Physical and rehabilitation medicine, medical rehabilitation
- Vol. 8 (2) , 124-148
Open AccessEpigenetic mechanisms in the pathogenesis of cardiovascular diseases and their significance for cardiac rehabilitation
The development and progression of cardiovascular diseases such as atherosclerosis, hypertension, coronary heart disease, heart failure, and others is determined by the interaction of genetic, environmental, and behavioral factors. In recent years, epigenetic mechanisms have been considered key regulators of the cardiovascular system, influencing gene expression without altering the DNA sequence. The expression of disease-associated genes is regulated by epigenetic mechanisms. The epigenome plays a key role in executing cellular programs, regulating gene transcription and altering chromatin structure and accessibility to transcription factors. Epigenetic enzymes depend on metabolites to perform their modifying functions, thereby establishing a link between metabolism and epigenetics. Cellular metabolic processes include glycolysis and β-oxidation of fatty acids, as well as energy metabolism. Cardiovascular metabolic dysfunction contributes to the development of cardiovascular disease through inappropriate epigenetic modifications of histone proteins, DNA, and RNA. Key elements of this process are transcription factors that interact with regulatory DNA sequences, altering gene expression. Advances in epigenome analysis have provided insights into the pathogenesis of cardiovascular diseases by identifying disease-associated epigenetic changes in cardiomyocytes and other cardiac cell types. This review examines recent discoveries in the field of epigenetic regulation of cardiac disease, highlighting the role of epigenetic enzymes and non-coding RNAs, which offer new opportunities for personalized medicine in cardiology. Understanding these epigenetic pathways is critical for the development of new biomarkers and epigenetic therapies and cardiac rehabilitation aimed at slowing or reversing maladaptive cardiac remodeling and improving clinical outcomes.
- Open Access
- 14 March 2026
- Published by Federal Research and Clinical Center for Resuscitation and Rehabilitation in Physical and rehabilitation medicine, medical rehabilitation
- Vol. 8 (1) , 44-63
COVID-19 as a trigger for the development or progression of neurodegenerative diseases
The legacy of the COVID-19 pandemic may represent an even more serious global health challenge than the acute infection itself. The neurological consequences of SARS-CoV-2 infection may progress to chronic brain tissue damage, leading to clinical manifestations of neurodegenerative diseases. Post-COVID-19 neurological syndrome and neurodegenerative disorders, such as Alzheimer disease and Parkinson disease, share common pathological features, risk factors, and underlying mechanisms. Immune-mediated mechanisms constitute a key component of the post-COVID-19 neurological syndrome and may initiate a neurodegenerative cascade. Chronic inflammatory processes triggered by SARS-CoV-2 infection promote the aggregation of misfolded proteins and neuronal loss, which are hallmark features of neurodegeneration. Given the high global prevalence of COVID-19 during the pandemic, health care systems should be prepared for a potential increase in the incidence of neurodegenerative diseases in the coming years. Addressing this challenge requires interdisciplinary collaboration integrating immunology, neurology, virology, and systems biology to develop effective individualized therapeutic strategies for one of the most persistent consequences of the COVID-19 pandemic. This review examines the complex relationship between COVID-19 and neurodegenerative diseases. SARS-CoV-2, its RNA, and proteins act as potent immunomodulatory agents capable of inducing chronic neuroinflammation even after viral clearance. Advances in modern biomedical technologies have enabled the identification of proteomic, genetic, and imaging biomarkers that may serve as predictors of risk and potential therapeutic targets. Elucidation of these molecular interactions provides important insights for future research aimed at developing innovative therapeutic and rehabilitation interventions.
- 14 March 2026
- Published by Federal Research and Clinical Center for Resuscitation and Rehabilitation in Physical and rehabilitation medicine, medical rehabilitation
- Vol. 8 (1) , 44-63
Open AccessCOVID-19 as a trigger for the development or progression of neurodegenerative diseases
The legacy of the COVID-19 pandemic may represent an even more serious global health challenge than the acute infection itself. The neurological consequences of SARS-CoV-2 infection may progress to chronic brain tissue damage, leading to clinical manifestations of neurodegenerative diseases. Post-COVID-19 neurological syndrome and neurodegenerative disorders, such as Alzheimer disease and Parkinson disease, share common pathological features, risk factors, and underlying mechanisms. Immune-mediated mechanisms constitute a key component of the post-COVID-19 neurological syndrome and may initiate a neurodegenerative cascade. Chronic inflammatory processes triggered by SARS-CoV-2 infection promote the aggregation of misfolded proteins and neuronal loss, which are hallmark features of neurodegeneration. Given the high global prevalence of COVID-19 during the pandemic, health care systems should be prepared for a potential increase in the incidence of neurodegenerative diseases in the coming years. Addressing this challenge requires interdisciplinary collaboration integrating immunology, neurology, virology, and systems biology to develop effective individualized therapeutic strategies for one of the most persistent consequences of the COVID-19 pandemic. This review examines the complex relationship between COVID-19 and neurodegenerative diseases. SARS-CoV-2, its RNA, and proteins act as potent immunomodulatory agents capable of inducing chronic neuroinflammation even after viral clearance. Advances in modern biomedical technologies have enabled the identification of proteomic, genetic, and imaging biomarkers that may serve as predictors of risk and potential therapeutic targets. Elucidation of these molecular interactions provides important insights for future research aimed at developing innovative therapeutic and rehabilitation interventions.
- Open Access
- 23 January 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (11) , 4570
Role of biobanks in studying frequencies of alleles associated with COVID-19 severity and outcome in the Russian population
Aim . To analyze the frequency and potential association with the severity and outcome of coronavirus disease (COVID-19) of MUC5B rs35705950, TERT rs2736100, TLR3 rs3775290, and TLR7 rs179008 polymorphisms. Material and methods . The study included blood samples from 4783 patients diagnosed with COVID-19 from the biobank of City Hospital № 40 (St. Petersburg). All patients signed informed consent to participate in the study. Genotyping was performed using real-time polymerase chain reaction. Statistical analysis included Fisher's exact test and multiple regression. Results . Polymorphism frequencies are comparable with the Genome Aggregation Database (gnomAD). Among all polymorphisms, only the AA genotype of the TLR7 gene showed a significant association with severe COVID-19. Two following potentially significant genotype interactions were also identified: TERT AA + TLR7 T in men and TERT CC + TLR3 CT in women. Conclusion. The results highlight the value of local biobanks for studying population-based patterns of allele distribution and identifying genetic factors influencing the course of infectious diseases.
- 23 January 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (11) , 4570
Open AccessRole of biobanks in studying frequencies of alleles associated with COVID-19 severity and outcome in the Russian population
Aim . To analyze the frequency and potential association with the severity and outcome of coronavirus disease (COVID-19) of MUC5B rs35705950, TERT rs2736100, TLR3 rs3775290, and TLR7 rs179008 polymorphisms. Material and methods . The study included blood samples from 4783 patients diagnosed with COVID-19 from the biobank of City Hospital № 40 (St. Petersburg). All patients signed informed consent to participate in the study. Genotyping was performed using real-time polymerase chain reaction. Statistical analysis included Fisher's exact test and multiple regression. Results . Polymorphism frequencies are comparable with the Genome Aggregation Database (gnomAD). Among all polymorphisms, only the AA genotype of the TLR7 gene showed a significant association with severe COVID-19. Two following potentially significant genotype interactions were also identified: TERT AA + TLR7 T in men and TERT CC + TLR3 CT in women. Conclusion. The results highlight the value of local biobanks for studying population-based patterns of allele distribution and identifying genetic factors influencing the course of infectious diseases.
- Open Access
- 20 October 2025
- Published by National Medical Research Center For Rehabilitation And Balneology in Bulletin of Rehabilitation Medicine
- Vol. 24 (5) , 73-83
Immunological aspects of physiotherapy according to the latest clinical studies: a review
INTRODUCTION. Physiotherapy interventions are typically employed during the rehabilitation phase or as an adjunct to primary therapy, such as pharmacological or surgical treatment, for patients with chronic or acute conditions. Interest in the immunological aspects of physiotherapy is growing rapidly. AIM. To summarize the data on the immunological aspects of physiotherapy presented in foreign publications of the last five years. MATERIALS AND METHODS. The search was conducted in the PubMed and Google Scholar databases using the following keywords: physiotherapy, immunology, innate immunity, acquired immunity, cellular immunity, humoral immunity, and clinical trials. Following the application of the exclusion criteria, 66 studies were selected from the initial 207 articles that were retrieved. THE MAIN CONTENT OF THE REVIEW. Chronic diseases, as well as the consequences of traumatic injuries, are characterized by chronic inflammation and immune imbalance. Despite impressive clinical successes of rehabilitation, it is not always effective in some patients, which highlights the need to understand and overcome the mechanisms of therapeutic refractoriness. Like other therapeutic modalities, physiotherapy faces the challenge of predicting patient response to intervention. It is assumed that the beneficial effects of physiotherapy are related to its anti-inflammatory, cytoprotective, and antioxidant properties and synergistic effects on immune functions. Our review article provides a concise overview of clinical studies exemplifying such effects, demonstrating the influence of physiotherapeutic manipulations on the population structure of the immune system and cytokine secretion. The review material is structured according to the main methods of physiotherapy, such as traditional methods (massage, treatment with heat, cold, water, mud, ultrasound, laser, magnetic field, hyperbaric oxygenation, pelotherapy), as well as newer ones (thermal and mechanical ablation with high-intensity ultrasound). CONCLUSION. The materials presented in the review offer a novel insight into the potential of physiotherapeutic interventions on both innate and acquired immunity, as well as their cellular and humoral components. The present state of research in this area is at an early stage. Further large-scale clinical studies are needed to develop recommendations for the safe use of immunomodulatory physiotherapy in the context of specific pathologies. In addition, physiotherapists should acquire additional knowledge in the field of immunology, which is currently beyond their competence, to accurately interpret and use the data.
- 20 October 2025
- Published by National Medical Research Center For Rehabilitation And Balneology in Bulletin of Rehabilitation Medicine
- Vol. 24 (5) , 73-83
Open AccessImmunological aspects of physiotherapy according to the latest clinical studies: a review
INTRODUCTION. Physiotherapy interventions are typically employed during the rehabilitation phase or as an adjunct to primary therapy, such as pharmacological or surgical treatment, for patients with chronic or acute conditions. Interest in the immunological aspects of physiotherapy is growing rapidly. AIM. To summarize the data on the immunological aspects of physiotherapy presented in foreign publications of the last five years. MATERIALS AND METHODS. The search was conducted in the PubMed and Google Scholar databases using the following keywords: physiotherapy, immunology, innate immunity, acquired immunity, cellular immunity, humoral immunity, and clinical trials. Following the application of the exclusion criteria, 66 studies were selected from the initial 207 articles that were retrieved. THE MAIN CONTENT OF THE REVIEW. Chronic diseases, as well as the consequences of traumatic injuries, are characterized by chronic inflammation and immune imbalance. Despite impressive clinical successes of rehabilitation, it is not always effective in some patients, which highlights the need to understand and overcome the mechanisms of therapeutic refractoriness. Like other therapeutic modalities, physiotherapy faces the challenge of predicting patient response to intervention. It is assumed that the beneficial effects of physiotherapy are related to its anti-inflammatory, cytoprotective, and antioxidant properties and synergistic effects on immune functions. Our review article provides a concise overview of clinical studies exemplifying such effects, demonstrating the influence of physiotherapeutic manipulations on the population structure of the immune system and cytokine secretion. The review material is structured according to the main methods of physiotherapy, such as traditional methods (massage, treatment with heat, cold, water, mud, ultrasound, laser, magnetic field, hyperbaric oxygenation, pelotherapy), as well as newer ones (thermal and mechanical ablation with high-intensity ultrasound). CONCLUSION. The materials presented in the review offer a novel insight into the potential of physiotherapeutic interventions on both innate and acquired immunity, as well as their cellular and humoral components. The present state of research in this area is at an early stage. Further large-scale clinical studies are needed to develop recommendations for the safe use of immunomodulatory physiotherapy in the context of specific pathologies. In addition, physiotherapists should acquire additional knowledge in the field of immunology, which is currently beyond their competence, to accurately interpret and use the data.
- Open Access
- 4 October 2025
- Published by Federal Research and Clinical Center for Resuscitation and Rehabilitation in Physical and rehabilitation medicine, medical rehabilitation
- Vol. 7 (3) , 221-242
Myocardial injury in COVID-19 and cardiac arrhythmias in acute and long-term periods
Epidemiologic data indicate that up to 30% of individuals surviving the acute phase of COVID-19 experience persistent cardiovascular symptoms, including dyspnea, chest pain and discomfort, palpitations, exercise intolerance, pathological fatigue, and sleep disturbances. Numerous investigations worldwide have shown that patients, regardless of age, race, sex, or cardiovascular risk factors, remain at increased risk for cardiovascular complications after recovery from COVID-19, including new-onset or progressive inflammatory heart diseases, heart failure, myocardial infarction, ischemic heart disease, cardiomyopathy, thromboembolism, cardiac arrhythmias, and ischemic stroke. SARS-CoV-2 not only induces direct cardiomyocyte injury or damages other cardiovascular system cells but also causes systemic inflammation and coagulopathy, which may exacerbate comorbid cardiovascular diseases. Functional and instrumental diagnostic methods have revealed various forms of subclinical and clinical cardiac injury in most patients with post-COVID syndrome, regardless of the severity of the acute COVID-19 phase or coexisting conditions. The high prevalence of post-COVID cardiovascular syndrome underscores the need for a comprehensive, multidisciplinary approach to diagnosis, treatment, and rehabilitation. Authors of published investigations, meta-analyses, and systematic reviews consistently emphasize the importance of monitoring cardiovascular status for at least one year after recovery from infection. This review article highlights the need to investigate the pathophysiology of post-COVID cardiovascular syndrome to identify potential therapeutic targets and develop targeted treatment strategies.
- 4 October 2025
- Published by Federal Research and Clinical Center for Resuscitation and Rehabilitation in Physical and rehabilitation medicine, medical rehabilitation
- Vol. 7 (3) , 221-242
Open AccessMyocardial injury in COVID-19 and cardiac arrhythmias in acute and long-term periods
Epidemiologic data indicate that up to 30% of individuals surviving the acute phase of COVID-19 experience persistent cardiovascular symptoms, including dyspnea, chest pain and discomfort, palpitations, exercise intolerance, pathological fatigue, and sleep disturbances. Numerous investigations worldwide have shown that patients, regardless of age, race, sex, or cardiovascular risk factors, remain at increased risk for cardiovascular complications after recovery from COVID-19, including new-onset or progressive inflammatory heart diseases, heart failure, myocardial infarction, ischemic heart disease, cardiomyopathy, thromboembolism, cardiac arrhythmias, and ischemic stroke. SARS-CoV-2 not only induces direct cardiomyocyte injury or damages other cardiovascular system cells but also causes systemic inflammation and coagulopathy, which may exacerbate comorbid cardiovascular diseases. Functional and instrumental diagnostic methods have revealed various forms of subclinical and clinical cardiac injury in most patients with post-COVID syndrome, regardless of the severity of the acute COVID-19 phase or coexisting conditions. The high prevalence of post-COVID cardiovascular syndrome underscores the need for a comprehensive, multidisciplinary approach to diagnosis, treatment, and rehabilitation. Authors of published investigations, meta-analyses, and systematic reviews consistently emphasize the importance of monitoring cardiovascular status for at least one year after recovery from infection. This review article highlights the need to investigate the pathophysiology of post-COVID cardiovascular syndrome to identify potential therapeutic targets and develop targeted treatment strategies.
- Open Access
GFAP as a Marker of Neuroinflammation in Patients with COVID-19: A Comparative Analysis with Alzheimer’s and Parkinson’s Disease
Background: Persistent neurocognitive symptoms following COVID-19 may stem from sustained neuroinflammation. Glial fibrillary acidic protein (GFAP) is a blood marker of astroglial activation; how it aligns COVID-19 with neurodegenerative diseases remains unclear. Methods: We compared plasma GFAP and a focused panel (fractalkine/CX3CL1, MDC/CCL22, sCD40L, IP-10/CXCL10, VEGFA) across patients hospitalized with COVID-19 who later developed post-COVID neurological symptoms (n=36), Alzheimer’s disease (AD, n=40), Parkinson’s disease (PD, n=44), and controls (n=30). Assays used xMAP Luminex (panel) and ELISA (GFAP). Non-parametric statistics (Kruskal–Wallis; Mann–Whitney, α=0.01) and multivariate analyses (PCA, LDA) were performed on log-transformed, standardized data in R 4.5.1. Results: GFAP was elevated versus controls in COVID-19 (median 308 pg/mL) and PD (475 pg/mL) and modestly increased in AD (250 pg/mL) compared with controls (194 pg/mL). COVID-19 showed a distinct inflammatory signature with markedly reduced fractalkine and MDC, and increased IP-10, while AD/PD exhibited higher sCD40L and VEGFA. GFAP did not differ between COVID-19 and AD, positioning astroglial activation as a shared axis. PCA/LDA placed COVID-19 between controls and AD/PD, indicating partial convergence with neurodegeneration yet a unique acute-inflammation profile. Conclusions: Blood GFAP aligns COVID-19 with AD/PD on astrocytic activation, whereas chemokine and platelet-activation markers distinguish COVID-19 from chronic neurodegeneration. These findings support composite biomarker panels for stratifying post-COVID neuroinflammation.
Open AccessGFAP as a Marker of Neuroinflammation in Patients with COVID-19: A Comparative Analysis with Alzheimer’s and Parkinson’s Disease
Background: Persistent neurocognitive symptoms following COVID-19 may stem from sustained neuroinflammation. Glial fibrillary acidic protein (GFAP) is a blood marker of astroglial activation; how it aligns COVID-19 with neurodegenerative diseases remains unclear. Methods: We compared plasma GFAP and a focused panel (fractalkine/CX3CL1, MDC/CCL22, sCD40L, IP-10/CXCL10, VEGFA) across patients hospitalized with COVID-19 who later developed post-COVID neurological symptoms (n=36), Alzheimer’s disease (AD, n=40), Parkinson’s disease (PD, n=44), and controls (n=30). Assays used xMAP Luminex (panel) and ELISA (GFAP). Non-parametric statistics (Kruskal–Wallis; Mann–Whitney, α=0.01) and multivariate analyses (PCA, LDA) were performed on log-transformed, standardized data in R 4.5.1. Results: GFAP was elevated versus controls in COVID-19 (median 308 pg/mL) and PD (475 pg/mL) and modestly increased in AD (250 pg/mL) compared with controls (194 pg/mL). COVID-19 showed a distinct inflammatory signature with markedly reduced fractalkine and MDC, and increased IP-10, while AD/PD exhibited higher sCD40L and VEGFA. GFAP did not differ between COVID-19 and AD, positioning astroglial activation as a shared axis. PCA/LDA placed COVID-19 between controls and AD/PD, indicating partial convergence with neurodegeneration yet a unique acute-inflammation profile. Conclusions: Blood GFAP aligns COVID-19 with AD/PD on astrocytic activation, whereas chemokine and platelet-activation markers distinguish COVID-19 from chronic neurodegeneration. These findings support composite biomarker panels for stratifying post-COVID neuroinflammation.
- Open Access
- 29 June 2025
- Published by Federal Research and Clinical Center for Resuscitation and Rehabilitation in Physical and rehabilitation medicine, medical rehabilitation
- Vol. 7 (2) , 134-153
Virtual Reality in Medical Rehabilitation
Patients with motor and/or cognitive disorders, a history of stroke or head/spinal cord injury, chronic pain, neurodegenerative diseases, or neurological complications of severe COVD-19 may not benefit from pharmacotherapy or traditional rehabilitation. Virtual reality is an innovative therapeutic approach that restores lost functions. This interactive technology uses computer modeling to create a virtual world. Virtual reality provides multisensory stimulation, activates restorative neural mechanisms, and produces an analgesic effect. In recent years, virtual reality has become more prevalent in neurology. It improves motor and cognitive outcomes in patients with various neurological and neuropsychological dysfunctions. These improvements are the result of neuroplasticity and neurogenesis in brain lesions. Virtual reality–based rehabilitation can be used alone or in combination with other treatment options. The most effective treatment combines exercise therapy, physical therapy, psychological counseling, standard cognitive training, and training with immersive virtual reality technology. This technology creates a sense of presence in a three-dimensional digital environment. With head-mounted displays and body monitoring sensors, users can interact naturally with virtual objects. Systematic reviews and meta-analyses have shown that depending on the initial condition, most patients demonstrate improvement in voluntary range of motion, balance, cognitive function, mood, quality of life, anxiety, and pain. Therefore, virtual reality–based therapy is a promising rehabilitation option for patients with neurological symptoms. Virtual reality–based neurological rehabilitation allows for the personalized selection of exercise complexity and intensity, thereby increasing patient compliance through gamification. However, further research is needed to standardize virtual reality–based modalities, clarify inclusion and exclusion criteria for clinical trials, optimize protocols, and evaluate long-term effects.
- 29 June 2025
- Published by Federal Research and Clinical Center for Resuscitation and Rehabilitation in Physical and rehabilitation medicine, medical rehabilitation
- Vol. 7 (2) , 134-153
Open AccessVirtual Reality in Medical Rehabilitation
Patients with motor and/or cognitive disorders, a history of stroke or head/spinal cord injury, chronic pain, neurodegenerative diseases, or neurological complications of severe COVD-19 may not benefit from pharmacotherapy or traditional rehabilitation. Virtual reality is an innovative therapeutic approach that restores lost functions. This interactive technology uses computer modeling to create a virtual world. Virtual reality provides multisensory stimulation, activates restorative neural mechanisms, and produces an analgesic effect. In recent years, virtual reality has become more prevalent in neurology. It improves motor and cognitive outcomes in patients with various neurological and neuropsychological dysfunctions. These improvements are the result of neuroplasticity and neurogenesis in brain lesions. Virtual reality–based rehabilitation can be used alone or in combination with other treatment options. The most effective treatment combines exercise therapy, physical therapy, psychological counseling, standard cognitive training, and training with immersive virtual reality technology. This technology creates a sense of presence in a three-dimensional digital environment. With head-mounted displays and body monitoring sensors, users can interact naturally with virtual objects. Systematic reviews and meta-analyses have shown that depending on the initial condition, most patients demonstrate improvement in voluntary range of motion, balance, cognitive function, mood, quality of life, anxiety, and pain. Therefore, virtual reality–based therapy is a promising rehabilitation option for patients with neurological symptoms. Virtual reality–based neurological rehabilitation allows for the personalized selection of exercise complexity and intensity, thereby increasing patient compliance through gamification. However, further research is needed to standardize virtual reality–based modalities, clarify inclusion and exclusion criteria for clinical trials, optimize protocols, and evaluate long-term effects.
- 27 May 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (4) , 43-53
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cerebrospinal fluid
Objective. To determine, evaluate, and analyze the diagnostic value of various laboratory biomarkers of Alzheimer’s disease (AD) in blood and cerebrospinal fluid (CSF). Material and methods. The concentrations of 93 potential biomarkers in plasma and CSF were studied in patients with AD at various stages (n=53) and independently in the group at the predementia stage (n=15). Results. Statistically significant correlations of various directions (p≤0.05) were found between the coefficients characterizing the amyloidosis and neurodegeneration (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) with markers associated with neuroinflammation, vascular disorders, angiogenesis, neuroimaging changes, and neuropsychological indicators. Previous studies of markers associated with inflammation in CSF in AD patients have shown mixed results, and no markers have been introduced into clinical practice so far. Many biomarkers associated with two classical pathogenetic links and other pathophysiological processes have been identified. Conclusion. Coefficients reflecting two main pathogenetic processes in CSF of AD patients (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) are the most informative for verifying two main links in the disease pathogenesis—amyloidogenesis and neurodegeneration. In the group of patients with amnestic mild cognitive impairment (aMCI), statistically significant relationships of cytokines associated with neuroinflammation, growth factors, and complement system protein with coefficients of amyloidosis and neurodegeneration in CSF, as well as PET, MRI, and neuropsychological tests were shown; therefore, these indicators can also be considered as potential diagnostic biomarkers of early stages and possible predictors of MCI conversion to dementia. Such markers as GFAP, apolipoprotein A1, GDF-15, IFN-γ, IL-5, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, VEGF, and complement C3 should be considered as objects for further research as biomarkers for early diagnosis.
- 27 May 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (4) , 43-53
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cerebrospinal fluid
Objective. To determine, evaluate, and analyze the diagnostic value of various laboratory biomarkers of Alzheimer’s disease (AD) in blood and cerebrospinal fluid (CSF). Material and methods. The concentrations of 93 potential biomarkers in plasma and CSF were studied in patients with AD at various stages (n=53) and independently in the group at the predementia stage (n=15). Results. Statistically significant correlations of various directions (p≤0.05) were found between the coefficients characterizing the amyloidosis and neurodegeneration (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) with markers associated with neuroinflammation, vascular disorders, angiogenesis, neuroimaging changes, and neuropsychological indicators. Previous studies of markers associated with inflammation in CSF in AD patients have shown mixed results, and no markers have been introduced into clinical practice so far. Many biomarkers associated with two classical pathogenetic links and other pathophysiological processes have been identified. Conclusion. Coefficients reflecting two main pathogenetic processes in CSF of AD patients (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) are the most informative for verifying two main links in the disease pathogenesis—amyloidogenesis and neurodegeneration. In the group of patients with amnestic mild cognitive impairment (aMCI), statistically significant relationships of cytokines associated with neuroinflammation, growth factors, and complement system protein with coefficients of amyloidosis and neurodegeneration in CSF, as well as PET, MRI, and neuropsychological tests were shown; therefore, these indicators can also be considered as potential diagnostic biomarkers of early stages and possible predictors of MCI conversion to dementia. Such markers as GFAP, apolipoprotein A1, GDF-15, IFN-γ, IL-5, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, VEGF, and complement C3 should be considered as objects for further research as biomarkers for early diagnosis.
- Open Access
- 11 April 2025
- Published by Federal Research and Clinical Center for Resuscitation and Rehabilitation in Physical and rehabilitation medicine, medical rehabilitation
- Vol. 7 (1) , 65-77
Immunological aspects of overtraining syndrome
Intensified training is a widely accepted approach to improving athletic performance. To achieve consistently high performance, athletes require a balance between training and recovery. Without adequate recovery and muscle rest, an athlete may progress from optimal training to overreaching and, ultimately, to overtraining syndrome, which negatively affects physical health and performance. The issue of overtraining syndrome remains an underexplored area in sports medicine. Monitoring of pre-competition training is crucial for adjusting training programs. Various physiological and biochemical markers are commonly used to assess athletic conditioning. Changes in these markers help coaches and athletes understand physical status and training effects as they reflect muscle condition, endurance, fatigue, and inflammation response in tissues. However, the sensitivity of individual biomarkers in detecting overtraining is limited, and reference ranges for different training levels are not clearly defined. Systematic assessment of pre-competition preparation and diagnosis of overtraining syndrome remain challenging as the factors, signs/symptoms, and mechanisms of maladaptation are individualized, sport-specific, and understudied. Thus, identification of biomarkers that could aid in monitoring athletic conditioning and preventing and diagnosing overtraining syndrome is a critical research objective.
- 11 April 2025
- Published by Federal Research and Clinical Center for Resuscitation and Rehabilitation in Physical and rehabilitation medicine, medical rehabilitation
- Vol. 7 (1) , 65-77
Open AccessImmunological aspects of overtraining syndrome
Intensified training is a widely accepted approach to improving athletic performance. To achieve consistently high performance, athletes require a balance between training and recovery. Without adequate recovery and muscle rest, an athlete may progress from optimal training to overreaching and, ultimately, to overtraining syndrome, which negatively affects physical health and performance. The issue of overtraining syndrome remains an underexplored area in sports medicine. Monitoring of pre-competition training is crucial for adjusting training programs. Various physiological and biochemical markers are commonly used to assess athletic conditioning. Changes in these markers help coaches and athletes understand physical status and training effects as they reflect muscle condition, endurance, fatigue, and inflammation response in tissues. However, the sensitivity of individual biomarkers in detecting overtraining is limited, and reference ranges for different training levels are not clearly defined. Systematic assessment of pre-competition preparation and diagnosis of overtraining syndrome remain challenging as the factors, signs/symptoms, and mechanisms of maladaptation are individualized, sport-specific, and understudied. Thus, identification of biomarkers that could aid in monitoring athletic conditioning and preventing and diagnosing overtraining syndrome is a critical research objective.